Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0RDRL | ISIN: GB00B3FLWH99 | Ticker-Symbol: 21T
Frankfurt
22.01.25
08:11 Uhr
7,450 Euro
-0,400
-5,10 %
Branche
Maschinenbau
Aktienmarkt
FTSE-250
1-Jahres-Chart
BODYCOTE PLC Chart 1 Jahr
5-Tage-Chart
BODYCOTE PLC 5-Tage-Chart
RealtimeGeldBriefZeit
7,4507,75022.01.
PR Newswire
318 Leser
Artikel bewerten:
(2)

Bodycote Plc - Extension of Share Buyback Programme

Finanznachrichten News

Bodycote Plc - Extension of Share Buyback Programme

PR Newswire

LONDON, United Kingdom, December 23

23 December 2024

Bodycote plc

Extension of share buyback programme

Further to the announcement made on 12 December 2024, Bodycote plc ("Company"), the world's leading provider of heat treatment and specialist thermal processing services, today confirms its intention to extend the current share buyback programme, as originally announced on 15 March 2024 ('Programme'), by a further £30 million, resulting in a total maximum aggregate consideration of £90 million being allocated to the Programme.

On 22 January 2024, Bodycote announced a plan to return £60 million to shareholders to be completed by March 2025. The first £30 million tranche of the Programme, undertaken by HSBC Bank plc ('HSBC'), commenced on 15 March 2024 and concluded on 23 July 2024. The second £30 million tranche of the Programme, which commenced on 30 July 2024 and is being undertaken by Jefferies, is now largely complete and will conclude by 30 January 2025.

The Company has now entered into a further agreement with HSBC to execute an additional £30 million share buyback as an extension to the original Programme (the 'Extended Programme') to start immediately following completion of the second tranche of the programme. Under this arrangement, HSBC will carry out on-market purchases of ordinary shares . HSBC will make its trading decisions in relation to the Extended Programme independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject during the Extended Programme.

The Extended Programme will otherwise continue to be subject to the same parameters, and for the same purpose, as set out in the Company's announcement of 15 March 2024, in particular with respect to the volume of shares that can be traded. The maximum number of shares which can be repurchased under the Programme is currently 13,408,869. The Extended Programme will be conducted at all times within the limits of the applicable authority granted by shareholders at the 2024 AGM to repurchase the Company's ordinary shares in issue and, post the 2024 AGM, if approval is granted by the shareholders, in accordance with the general authority to repurchase shares granted at that meeting. It is anticipated that the Extended Programme will end no later than July 2025.

This Extended Programme will be conducted in accordance with the Company's general authority to repurchase Ordinary Shares, Chapter 9 of the FCA's Listing Rules, and in accordance with the parameters prescribed by the Market Abuse Regulation 596/2014 (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018). Share purchases in relation to the Extended Programme will be carried out on the open market via the London Stock Exchange and/or other recognised investment exchange(s) for the purposes of section 693 of the Companies Act 2006 and may be made from time to time depending on market conditions, share price, trading volume and other factors. Purchases may continue during any closed period to which the Company is subject during the engagement period.

About Bodycote

With more than 155 accredited facilities in 22 countries, Bodycote is the world's largest provider of thermal processing services. Through Specialist Technologies and Precision Heat treatment, Bodycote improves the properties of metals and alloys, extending the life of vital components for a wide range of industries, including aerospace, defence, automotive, power generation, medical, oil & gas, construction, and transportation. Customers in all of these industries have entrusted their products to Bodycote's care for more than 50 years. For more information, visit www.bodycote.com.

For further information, please contact:

Bodycote plc

Jim Fairbairn, Chief Executive Officer

Ben Fidler, Chief Financial Officer

Peter Lapthorn, Investor Relations and FP&A

Tel: +44 1625 505 300

FTI Consulting

Richard Mountain

Susanne Yule

Tel: +44 203 727 1340




© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.